Safety and Immunogenicity of a Recombinant Parvovirus B19 Vaccine Formulated with MF59C.1
W. Ripley Ballou(Walter Reed Army Institute of Research), Scott Koenig(MacroGenics (United States)), Jennifer L. Reed(Cincinnati Children's Hospital Medical Center), W. C. Noble, Neal S. Young(National Institutes of Health)
Cited by 134
Related Papers
MEDI-563, a humanized anti–IL-5 receptor α mAb with enhanced antibody-dependent cell-mediated cytotoxicity function
|Journal of Allergy and Clinical Immunology|2010|583
Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial
|The Lancet|2001|528
A comparison of self-reported and device measured sedentary behaviour in adults: a systematic review and meta-analysis
|International Journal of Behavioral Nutrition and Physical Activity|2020|525
Establishing the Minimal Clinically Important Difference for the Hospital Anxiety and Depression Scale in Patients With Cardiovascular Disease
|Journal of Cardiopulmonary Rehabilitation and Prevention|2018|283
Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial
|The Lancet Infectious Diseases|2015|217